Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Olivia Brayer initiated coverage of Inhibikase Therapeutics (IKT) with an Overweight rating and $4 price target Inhibikase is now essentially defined by IKT-001, its oral imatinib prodrug being advanced directly into a pivotal Phase 3 for pulmonary arterial hypertension despite limited drug-specific data, the analyst tells investors in a research note. The program rests on a strong mechanistic rationale, which positions IKT-001 as a higher-risk but credible contender in a market increasingly focused on disease-modifying therapies, Cantor says.